In 2013, French scientist Emmanuelle Charpentier co-founded CRISPR Therapeutics, a company that employed CRISPR-based gene-editing as a means of gene therapy to treat certain diseases in humans. The company was headquartered in Zug, Switzerland, with operations in Cambridge, Massachusetts. Charpentier served on the companyās scientific advisory board. Her involvement came after her contributions to the discovery of the CRISPR-Cas9 mechanism, which was successfully used to target and modify specific DNA sequences in the genomes of different organisms.
verifiedCite
While every effort has been made to follow citation style rules, there may be some discrepancies.
Please refer to the appropriate style manual or other sources if you have any questions.
Select Citation Style